Market Assessment: Strategic Decisions for Investing or Divesting into an Oncological Asset

Objective: Capturing Portfolio Potential in Immuno-Oncology

The aim of the study by DelveInsight Business Research LLP (featured in its “Immune Checkpoint Inhibitor Market Potential” case-study) was to evaluate the market potential of a recently acquired oncological asset, specifically in the immune-checkpoint inhibitor (ICI) space, and to assess whether the company should continue investing in development or divest the asset to streamline its portfolio. The strategic decision hinges on long-term value creation, alignment with core pipeline assets, and resource allocation in a crowded and fast-moving immuno-oncology environment.

Problem Statement: Crossroads for a Novel Oncology Asset

A leading global pharmaceutical company acquired a mid-cap biotech firm with a novel asset that complements its in-house ICI programme. The question: Should the company double-down on this asset for long-haul development, or divest it and redirect resources? The challenge arises from the high cost of late-stage oncology development, uncertain differentiation amid existing ICIs, and evolving market access/reimbursement dynamics. The decision required rigorous market assessment: therapeutic positioning, competitive benchmarking, clinical risk, and financial modelling.

Our Methodology: Multi-angle Intelligence for Actionable Insight

DelveInsight applied a robust methodology combining secondary research, primary stakeholder interviews, competitive intelligence, clinical-trial deep dives, and quantitative market modelling.

• Secondary research: reviewing published clinical data, regulatory filings, historical market trends for ICIs.
• Primary research: engaging oncologists, payers, researchers to gauge perceptions, prescribing habits and unmet needs.
• Competitive benchmarking: comparing the new asset against marketed and pipeline ICIs (efficacy, safety, differentiation, price/reimbursement).
• Clinical-trial analysis: dissecting endpoints, trial design, regulatory probability.
• Market forecasting: projecting market size, revenue trajectories, growth drivers/barriers across scenarios.

Throughout, DelveInsight offers clients therapeutic-area insight, disease-landscape modelling, competitor profiles and quantitative forecasts, enabling evidence-based strategic decisions.

Results: Strategic Clarity and Roadmap for Action

The assessment delivered a suite of outputs: executive-level analysis of strategic fit, disease-landscape breakdown, treatment-algorithm mapping, market drivers/barriers, SWOT, competitor overview, revenue forecast under multiple scenarios. 

In practical terms, the company gained:

• A clear view of how the new asset would slot into current therapeutic pathways and its differentiation potential.
• Forecasts of market size and revenue under “invest further” versus “divest or partner” scenarios.
• Strategic recommendations: whether to continue internal development, seek licensing/partnering, or divest for faster capital recovery.

By doing so, DelveInsight enabled the client to move from uncertainty to a reasoned decision - backed by data - about whether to invest or divest an oncological ICI asset.

In conclusion, for firms navigating the high-stakes immuno-oncology arena, having a partner like DelveInsight offers invaluable clarity: deep market and clinical intelligence, competitive insight, and financial modelling essential for making strategic timing and investment decisions in an arena where speed, differentiation and access matter critically.

Step into the future of pharma research with MarketAI - your all-in-one platform for uncovering market trends, benchmarking competitors, and identifying growth opportunities. Make informed decisions faster with AI-powered intelligence at your fingertips @ AI Powered Pharma Intelligence Platform